Article Text
PDFNeurology in practice
The bare essentials
Parkinson's disease
Statistics from Altmetric.com
Footnotes
-
Competing interests AL has received honoraria for advisory boards from Roche, Novartis, Orion, Boehringer Ingelheim, GSK, Britannia Pharmaceuticals, Solvay and Medtronic and has a consultancy agreement with Britannia Pharmaceuticals.
-
Provenance and peer review Commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Improving the diagnostic accuracy in parkinsonism: a three-pronged approach
- Parkinson's disease: chameleons and mimics
- Parkinson’s disease: clinical features and diagnosis
- Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism
- Is it Parkinson’s disease, and if not, what is it?
- DIAGNOSIS AND MANAGEMENT OF ATYPICAL PARKINSONIAN SYNDROMES
- Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes
- Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines
- The role of DAT-SPECT in movement disorders
- How useful is [123I]β-CIT SPECT in clinical practice?